Skip to main content
. 2014 Nov 26;2014(11):CD007403. doi: 10.1002/14651858.CD007403.pub3
    Analgesia  
Study ID Treatment Outcome measure Success Rescue Medication
Acute        
Diebschlag 1987 (1) Salicylate, adrenal extract, and mucopolysaccharide ointment (Mobilat)
(2) Placebo ointment
Movement pain on 100 mm VAS at:
(a) 8 days
(b) 15 days
No dichotomous data
(a) Significant difference in favour of (1)
(b) Significant difference in favour of (1)
No data
Frahm 1993 (1) Salicylate and mucopolysaccharide cream (Movelat)
(2) Placebo cream
Movement pain on 100 mm VAS at:
(a) 9 days
(b) 11 days
No dichotomous data
(a) Significant difference in favour of (1)
(b) No significant difference
No data
Ginsberg 1987 (1) Salicylate and capsicum oleoresin ointment (Rado‐Salil)
(2) Placebo ointment
Patient global assessment ('excellent' or 'good') at:
(a) 3 days
(b) 14 days
(a)
(1) 5/20
(2) 0/20
(b)
(1) 10/20
(2) 2/20
Total number of rescue tablets (250 mg paracetamol) used:
(1) 24
(2) 36
Ibanez 1988 (1) Salicylate spray
(2) Fepradinol spray active control
"Cure" at 12 days (1) 23/35
(2) 85/102
No data
Lester 1981 (1) Salicylate, adrenal extract, and mucopolysaccharide gel (Movelat)
(2) Placebo gel
Relief of pain by 7 days (1) 18/20
(2) 13/22
No data
Rothhaar 1982 (1) Salicylate gel (Reparil‐Gel)
(2) Placebo gel
Patient global assessment ('very good' or 'good') at 9 days (1) 37/39
(2) 3/42
No data
Stam 2001 (1) Salicylate, nicotinate, capsicum oleoresin, and histamine gel (Cremor Capsici Compositus FNA)
(2) Herbal gel (Spiroflor SRL) active control
80% reduction in pain on 100 mm VAS at 7 days (1) 41/78
(2) 40/83
Number using rescue medication (paracetamol):
(1) 65/82
(2) 56/75
Chronic        
Algozzine 1982 (1) Salicylate cream (Myoflex)
(2) Placebo cream
Pain relief score at 7 days favours (1) or (2) No first period data. Combined periods: (1) 10/25
(2) 8/25
No data
Camus 1975 (1) Salicylate and myrtecaine cream (Algesal Suractive)
(2) Placebo cream
Improvement in rest pain score at 10 days (1) 8/10
(2) 3/10
No data
Geller 1980 (1) Salicylate and heparin gel (Dolo‐Menthoneurin)
(2) Etofenamate gel active control
Patient global score ('very good' or 'good') after phase 1 at 7 days First period data
(1) 24/25
(2) 8/25
No data
Golden 1978 (1) Salicylate cream (Aspercreme) + placebo tablets
(2) Aspirin tablets + placebo cream active control
Patient global assessment of pain relief ('excellent' or 'good') at 7 days (1) 13/20
(2) 10/20
No data
Lobo 2004 (1) Salicylate cream (Theraflex‐TMJ)
 (2) Placebo cream Spontaneous pain VAS (10 cm) at:
(a) 15 days
(b) 10 days
No dichotomous data
(a) Significant difference in favour of (1)
(b) No significant difference
No data
Rutner 1995 (1) Salicylate gel (Phardol‐Mono)
(2) Placebo gel
Dropout 'pain free' by day 14 (1) 21/54
(2) 18/59
No data
Shackel 1997 (1) Salicylate gel
(2) Placebo gel
Patient global assessment ('very good' or 'good') at 28 days (1) 22/58
(2) 21/56
Number using rescue medication (paracetamol):
(1) 43/56
(2) 39/55
 
 Average dose (mg/day):
(1) 555
(2) 600
von Bach 1979 (1) Salicylate and nonivamide in heparin and salicylate ointment (Enelbin‐Rheuma)
(2) Salicylate in heparin and salicylate ointment active control
Global assessment ('very good' or 'good') at 14 days (1) 27/50
(2) 10/50
No data
Wanet 1979 (1) Salicylate and myrtecaine cream (Algesal Suractive)
(2) Placebo cream
Rest pain score at 15 days (1) 15/32
(2) 4/24
No data
Zahmatkash 2011 (1) Salicylate ointment
(2) Herbal (cinnamon, ginger, mastic, sesame oil) ointment
Reduction in pain intensity (group mean) 14 days
(1) 13/100
(2) 13/100
28 days
(1) 19/100
(2) 21/100
42 days
(1) 22/100
(2) 25/100
No data
VAS: visual analogue scale